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1298Objective: The purpose of the investigation was to study the impact of normovolemic modified ultrafiltration
(N-MUF) on hemostasis and perioperative blood loss.
Methods: Fifty patients scheduled for elective complex cardiac surgery were enrolled in this prospective,
randomized, and controlled study. Patients were randomized into a control group (n ¼ 25) or an N-MUF
group (n ¼ 25). N-MUF was performed using a BC140plus Filter (Maquet Cardiopulmonary AG, Hirrlin-
gen, Germany) in the N-MUF group. Blood samples were taken before (T1) and 30 minutes after (T2)
N-MUF in the N-MUF group and at corresponding time points in the control group. Platelet function anal-
yses (TRAPtest, ASPItest, ADPtest) using multiple electrode aggregometry (Multiplate, Dynabyte, Munich,
Germany), thrombelastometry (ROTEM, Pentapharm GmbH, Munich, Germany), and conventional labora-
tory coagulation analyses were performed at each time point. Intraoperative and postoperative transfusion
requirements, hemostatic therapy, and blood loss were recorded.
Results: There were no significant group differences in demographic or surgical data. At T1, platelet aggrega-
tion revealed no significant group differences in the TRAPtest, ASPItest, or ADPtest. Platelet aggregation at T2
was significantly higher in the N-MUF group compared with the control group in the TRAPtest (65 [50/87] U vs
44 [28/51]; P<.001), the ASPItest (52 [36/69] U vs 22 [8/47] U; P¼ .001), or the ADPtest (39 [28/51] U vs 28
[19/39] U; P¼ .009). The postoperative chest tube blood loss was significantly lower in the N-MUF at 24 hours
(890 [500/1100] mL vs 1075 [800/1413] mL in the N-MUF group vs the control group; P ¼ .039) and 48 hours
(900 [550/1350] mL vs 1400 [900/1750] mL; P ¼ .026) postoperatively. Conventional laboratory coagulation
analyses and thrombelastometric parameters did not differ within the groups at T1 or T2.
Conclusions: N-MUF improved general platelet aggregation and reduced postoperative blood loss in a signifi-
cant manner. However, performing N-MUF did not result in less postoperative transfusion requirements.
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The Journal of Thoracic and Cardiovascular Sursuch as renal failure, sepsis, atrial arrhythmias, prolonged
requirement for mechanical ventilatory support, prolonged
hospitalization, and increased mortality.1 In particular, pa-
tients undergoing complex cardiac surgery procedures
with cardiopulmonary bypass (CPB) are at increased risk
for severe intraoperative and postoperative coagulopathy.
In addition to dilution, consumption, and activation of coag-
ulation factors, an imbalance between the coagulation and
fibrinolytic system, especially a CPB-induced complex
platelet dysfunction, has been shown to be the most impor-
tant hemostatic abnormality in this setting.2
Since the 1970s, several blood filtration techniques have
been proposed to prevent or attenuate the adverse effects of
CPB on hemostasis. In particular, in pediatric patients
undergoing cardiac surgery, the so-called modified ultrafil-
tration (MUF) method was adopted as standard practice in
75% of pediatric centers in North America to mitigate the
distinctive hemodilution caused by CPB.3 When perform-
ing hemoconcentration, this technique removes free water
excess after terminating CPB. In this context, MUFgery c May 2011
Abbreviations and Acronyms
aPTT ¼ activated partial thromboplastin time
CPB ¼ cardiopulmonary bypass
INR ¼ international normalized ratio
MEA ¼ multiple electrode aggregometry
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Mis known to be associated with clinical benefits, such as in-
creased hematocrit and platelet count,4,5 improved
pulmonary performance after reperfusion of the lungs,6 im-
proved cardiovascular function,7 and reduced postoperative
chest tube blood loss in pediatric patients.8
In contrast with pediatric patients, blood filtration during
or after CPB is not a part of the standard procedure in adult
patients. Its influence on the coagulation system, perioper-
ative blood loss, and the clinical outcome in general remains
controversial.9-11 The aim of the present study was to
determine the influence of normovolemic MUF (N-MUF)
on perioperative hemostasis, with special regard on
platelet function.
MATERIALS AND METHODS
This prospective, randomized, and controlled monocenter study com-
plies with the Declaration of Helsinki and was approved by the local scien-
tific and ethic review board. All patients gave written informed consent.
Before collecting the data, the study was registered online at
ClinicalTrials.gov (Identifier: NCT00998647).
Study Design
Patients were eligible for study inclusion if they underwent elective
complex cardiac surgery. Complex cardiac surgery was defined as com-
bined procedures, double-valve surgery, aortic surgery, and reoperations.
Further inclusion criteria were defined as age more than 65 years, euro-
SCORE more than 5, and expected duration of extracorporeal circulation
more than 120 minutes. The exclusion criterion was patients’ failure to ob-
tain consent. A total of 50 consecutive patients at the Department of Tho-
racic and Cardiovascular Surgery of J.-W. Goethe University Hospital
Frankfurt, Germany, were enrolled in this study between April 2009 and
February 2010. Patients were preoperatively assigned to a control group
(n ¼ 25) or an N-MUF group (n ¼ 25) by block-wise randomization.
Sociodemographic data, including preoperative antiplatelet therapy,
were recorded. Surgical data, perioperative blood loss, and hemostatic ther-
apy, including transfused blood products and coagulation factor concen-
trates up to 48 hours postoperatively, were assessed. Hematologic
analyses were performed 30 minutes before and after N-MUF (or at corre-
sponding time points in the control group) and included routine conven-
tional laboratory, thrombelastometric, and platelet function analyses.
No hemostatic therapy was performed during and up to 30 minutes after
N-MUF (T2). The primary end point was the arachidonic acid induced
ex vivo platelet aggregation in multiple electrode aggregometry (MEA,
ASPItest). Secondary end points were the results of conventional labora-
tory, thrombelastometric, and remaining platelet function analyses and
the perioperative blood loss.
Anesthetic Management
Anesthetic, operative, CPB, and coagulation management were stan-
dardized. No changes in surgical, anesthetic, or perfusion techniquesThe Journal of Thoracic and Carwere made for the purpose of the study. On the day before the surgery,
the patients were treated with 20 mg dikaliumclorazepat (Tranxilium,
Sanofi-Aventis GmbH, Hoechst, Germany) for premedication. General an-
esthesia was induced with 0.3 to 1 mg/kg sufentanil (Sufenta, Janssen-Cilag
GmbH, Neuss, Germany), 1 to 2.5 mg/kg propofol (Disoprivan, AstraZe-
neca GmbH, Wedel, Germany), and 0.6 mg/kg rocuronium (Esmeron,
Essex GmbH, Munich, Germany). The maintenance of general anesthesia
was achieved using 1 to 2 Vol% sevoflurane (Sevoran, Abbott, Wiesbaden,
Germany) and intermittent boli of sufentanil until the transfer to an in-
tensive care unit. All patients were orally intubated and mechanically
ventilated using a LeonPlus anesthesia machine (Heinen & Loewenstein,
Bad Ems, Germany). Packed red blood cell concentrates were transfused
to maintain a hematocrit greater than 18% during and 25% after CPB.Management of Extracorporeal Circulation and
Normovolemic Modified Ultrafiltration
The extracorporeal circuit included a membrane oxygenator (Quadrox
oxygenator, Maquet Cardiopulmonary AG, Hirrlingen, Germany) and
a roller pump system (HL20, Maquet Cardiopulmonary AG) equipped
with a heat exchanger (Plegiox, Maquet Cardiopulmonary AG). The circuit
was primed anterogradely with 500 mL crystalloid solution (Sterofundin,
B.Braun Melsungen AG, Melsungen, Germany), 500 mL colloid solution
(6% HES 130/0.4, Voluven, Fresenius Medical Care AG, Bad Homburg,
Germany), and 250 mL 20% Mannitol (Mannitol Baxter, Baxter, Unters-
chleissheim, Germany) according to institutional standards. Heparin
(Heparin-Natrium Braun, B.Braun Melsungen AG) was administered re-
petitively to maintain an activated clotting time of more than 400 seconds
after an initial bolus of 400 IE/kg. During CPB, a nonpulsatile flow was
maintained at 2.6 to 3 L/min/m2, and the mean arterial blood pressure
was targeted at 50 to 70 mm Hg by the addition of norepinephrine (Arter-
enol, Sanofi-Aventis GmbH), if needed. Myocardial protection was
achieved with cold blood cardioplegia (20C). An antifibrinolytic therapy
consisted of the application of 2 g tranexamic acid (Cyclocapron, MEDA
Pharma GmbH & Co KG, Bad Homburg, Germany) after induction of an-
esthesia, and another 2 g was added into the priming volume of the heart-
lungmachine and during CPB, respectively. Extracorporeal circulation was
performed in mild hypothermia. When surgery was completed, patients
were rewarmed to 36C and weaned from CPB. To reverse the anticoagu-
lant effects of heparin, protamine sulfate (Protaminsulfat, Novo Nordisk
Pharma GmbH, Vienna, Austria) was administered guided by activated
clotting time.
N-MUF was started after the protamine infusion. A hemofilter (BC 140
plus; Maquet Cardiopulmonary AG) with a surface area of 1.35 m2, a prim-
ing volume of 98mL, amaximal transmembranous gradient of 600mmHg,
a luminal diameter of 215 mm, and a membrane thickness of 50 mm was
used. The hemofilter was placed in the CPB circuit with blood coming in
from the arterial site and returning to the venous site. Accelerated by the
roller pump, the blood flow through the filter was 500 mL/min, and the ul-
trafiltration rate was 150 mL/min. To maintain normovolemia, a simulta-
neous infusion of 150 mL/min crystalloid solution (Multibic Kaliumfrei,
FreseniusMedical Care AG) was administered to the patient using a second
roller pump. N-MUF was stopped after a filtration volume of 3000 mL.Blood Sampling
Blood samples were taken before (T1) and 30 minutes after (T2)
N-MUF in the N-MUF group and at corresponding time points in the con-
trol group, respectively, from a preoperatively placed central venous line.
The first 10 mL of blood was discarded. For conventional laboratory coag-
ulation and ROTEM analyses, blood was collected into 3-mL tubes con-
taining sodium citrate as anticoagulant (Sarstedt AG, N€urnbrecht,
Germany) and a 4.7-mL EDTA tube (Sarstedt AG). For MEA (Multiplate)
analyses, the blood was collected into 2-mL heparin-anticoagulated and
calcium-balanced tubes (Bloodgas-Monovette, Sarstedt AG).diovascular Surgery c Volume 141, Number 5 1299
TABLE 1. Demographic and surgical data and hemostatic therapy in
the first 48 hours postoperatively
Control group
n ¼ 25
N-MUF group
n ¼ 25 P
Sex, male (%) 16 (64) 13 (52) .673
Age, y 75  5 74  6 .434
BMI, kg/m2 26  4 26  4 .972
Single antiplatelet therapy
until the day before surgery
4 (16) 6 (24) .54
Dual antiplatelet therapy until
the day before surgery
3 (12) 3 (12) 1.0
euroSCORE 7 (6/9) 7 (6/8) .425
CPB duration, min 160  63 146  50 .420
CABG and valve surgery (%) 20 (80) 19 (76) .278
Double valve surgery (%) 4 (16) 4 (16) 1.0
Aortic surgery (%) 1 (4) 2 (8) 1.0
Reoperations (%) 5 (20) 4 (16) .549
PRBC
[U]
5 (4/5)
(n ¼ 25/25)
4 (4/5)
(n ¼ 25/25)
.513
FFP
[U]
3 (3/4)
(n ¼ 14/25)
4 (3/4)
(n ¼ 12/25)
.126
PC
[U]
2 (2/3)
(n ¼ 10/25)
2 (2/2)
(n ¼ 9/25)
.801
Fibrinogen
[g]
4 (2/4)
(n ¼ 15/25)
4 (3/4)
(n ¼ 13/25)
.341
PCC
[IE]
1200 (1200/1800)
(n ¼ 11/25)
1200 (1200/1800)
(n ¼ 8/25)
.782
BMI, Body mass index;CPB, cardiopulmonary bypass; PRBC, packed red blood cell;
FFP, fresh-frozen plasma; PC, platelet concentrate; PPC, prothrombin complex con-
centrate. Values are presented as the median (25th/75th percentiles), mean standard
deviation, or number (%).
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Conventional laboratory analyses. Platelet count, fibrinogen
concentration, international normalized ratio (INR), activated partial
thromboplastin time (aPTT), and hematocrit were performed in the local
central laboratory using the fully automated coagulation analyzer STA-R
Evolution (Roche AG, Grenzach, Germany) and SysmexXE 2001 (Sysmex
GmbH, Norderstedt, Germany).
Multiple electrode aggregometry. MEA was performed using
the Multiplate analyzer, a whole blood impedance aggregometer (Dyna-
byte, Munich, Germany) based on impedance aggregometry described by
Cardinal and Flower.12 The device has 5 test cells for parallel testing,
and each test cell incorporates 2 independent sensor units. The analysis
is based on the aggregation of the activated platelets onto metal sensor
wires in the test cell, which increases the electrical impedance between
the wires. For measurement, 300 mL of preheated saline (37C) and
300 mL of heparin-anticoagulated whole blood were placed into the test
cell, and the sample was stirred using a Teflon-coated electromagnetic stir-
rer (800 rpm) over a 3-minute incubation period. Platelet aggregation was
initiated using 32 mmol/L thrombin receptor activating peptide (TRAP-6,
TRAPtest), 0.5 mmol/L arachidonic acid (ASPItest), or 6.4 mmol/L ADP
(ADPtest) using commercially available reagents (Dynabyte). Increased
impedance due to the attachment of platelets to the electrodes was contin-
uously and separately measured by each sensor unit over 6 minutes. The
data were transformed into arbitrary aggregation units (AU) and plotted
as 2 separate aggregation curves against time. The aggregation measured
by MEAwas quantified as the area under the aggregation curve (U). The
reference ranges for healthy subjects obtained from the manufacturer
were 87 to 147 U for the TRAPtest, 51 to 109 U for the ASPItest, and
61 to 96 U for the ADPtest.
Thrombelastometry. Thrombelastometry was performed by
a 4-channel ROTEMdevice (PentapharmGmbH,Munich, Germany) based
on the classic thrombelastography described by Hartert.13 The technical
and methodological details of ROTEM have been described.14,15 Four
tests were performed according to the manufacturer’s instructions: The
EXTEM- and INTEM-test reflect the extrinsic and intrinsic initiation of
coagulation, respectively, the FIBTEM-test (platelet-inhibited extrinsic
activation) reflects plasmatic contributors to clot firmness, and the
HEPTEM-test (heparinase-modified intrinsic activation) to identify hepa-
rin effects in comparison with the INTEM-test. Clotting time (seconds)
in EXTEM, INTEM, and HEPTEM tests and the maximum clot firmness
(millimeters) in each test were recorded.
Postoperative Blood Loss
The chest tube blood loss was assessed 6, 12, 24, and 48 hours postop-
eratively.
Statistical Analyses
The statistical analyses were performed using SigmaStat (Version 3.5,
Systat Software GmbH, Erkrath, Germany) and SigmaPlot (Version 11,
Systat Software GmbH) software. Sample size analysis was based on sug-
gested changes in arachidonic acid induced ex vivo platelet aggregation
with an expected difference of means for ASPItest of 15 U, an expected
standard deviation of 25 U (desired power ¼ 0.8, and P< .05), which
was based on previous pilot investigation. The analysis revealed a required
sample size of at least n ¼ 24 in each group to detect statistically signifi-
cant differences between the groups. Depending on the distribution of
the data (Kolmogorov–Smirnov–Test), t tests and paired t tests or the
Mann–Whitney rank-sum test and Wilcoxon signed-rank test were used
to describe differences between the groups and the measuring points, re-
spectively. Fisher’s exact test was used to detect differences between the
proportions of patients with respect to categoric data. The values are
expressed as the mean  standard deviation or median (25th/75th
percentiles).1300 The Journal of Thoracic and Cardiovascular SurRESULTS
Demographic parameters, surgical data, transfusions, and
hemostatic therapy are described in Table 1. We detected no
significant group differences of the prevalence of patients
being treated with single antiplatelet (100 mg/d aspirin) or
dual antiplatelet (100mg/d aspirin and 75mg/d clopidogrel)
therapy until the day before surgery (Table 1).Multiple Electrode Aggregometry Results
The results of MEA analyses are shown in Figure 1. The
baseline measurements at T1 revealed no significant group
differences in the TRAPtest (48 [34/63] U vs 55 [33/91] U
in the control group vs the N-MUF group, respectively;
P ¼ .431), the ASPItest (26 [11/54] U vs 29 [16/48] U in;
P ¼ .736), or the ADPtest (30 [19/39] U vs 30 [16/46] U
in; P ¼ .869).
In contrast, platelet aggregation at T2 was significantly
higher in the N-MUF group compared with the control
group in the TRAPtest (44 [28/51] U vs 65 [50/87] U in
the control group vs the N-MUF group, respectively;
P<.001), the ASPItest (22 [8/47] U vs 52 [36/69] U in;
P ¼ .001), or the ADPtest (28 [19/39] U vs 39 [28/51] U
in; P ¼ .009).gery c May 2011
FIGURE 1. Ex vivo platelet aggregation inMEA at T1 and T2.Horizontal
dashed lines indicate the lower limit of the reference range for normal
platelet aggregation. *P<.05; n ¼ 50.
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MBetween T1 and T2, platelet aggregation significantly
improved in the N-MUF group in each of the tests
(55 [33/91] U vs 65 [50/87] U at T1 vs T2 for the TRAPt-
est; P ¼ .047, 29 [16/48] U vs 52 [36/69] U for the ASPIt-
est; P ¼ .025 and 30 [16/46] U vs 39 [28/51] U for the
ADPtest; P¼ .016). In contrast, MEA remained unchanged
in the control group between T1 and T2 (48 [34/63] U at
T1 vs 44 [28/51] U at T2 for the TRAPtest; P ¼ .121, 26
[11/54] U vs 22 [8/47] U for the ASPItest; P ¼ .160
and 30 [19/39] U vs 28 (19/39) U for the ADPtest;
P ¼ .143).The Journal of Thoracic and CarConventional Laboratory Coagulation Analyses and
Thrombelastometry
pH, calcium, temperature, hemoglobin, platelet count, fi-
brinogen INR, and aPTT did not differ at the corresponding
time points between the groups. We did not detect any
significant group differences in thrombelastometric param-
eters (Table 2).Postoperative Blood Loss, Blood Product Use, and
Rate of Rethoracotomies
We detected no significant group differences concerning
the 6 hours (450 [263/725] mL vs 450 [275/688] mL in the
control group vs the N-MUF group, respectively; P¼ .883)
or 12 hours (650 [413/961] mL vs 600 [400/988] mL;
P ¼ .863) postoperative blood loss. Blood loss was signifi-
cantly lower 24 hours (1075 [800/1413] mL vs 890 [500/
1100] mL; P ¼ .039) and 48 hours (1400 [900/1750] mL
vs 900 [550/1350] mL; P ¼ .026) postoperatively in the
N-MUF group (Figure 2).
There were no group differences in the proportion of pa-
tients who underwent surgical reexploration for bleeding
(n ¼ 2 in each group, P ¼ 1.0). Furthermore, we detected
no significant group differences with respect to the perio-
perative transfusion rate of allogenic blood products, in-
cluding packed red blood cell concentrates, fresh-frozen
plasma, and platelet concentrates or coagulation factor
concentrates (Table 1).DISCUSSION
The main findings of the present study were that N-MUF
after CPB was associated with i) a significant general im-
provement of platelet function as assessed by MEA and
ii) a significant reduction in postoperative blood loss.
In view of normal reference ranges, MEA results showed
a distinctively impaired platelet aggregation at T1 in both
groups and thereby reflected the known effect of CPB on
the induction of platelet dysfunctions.16,17 Our results
showed a significant improvement of platelet aggregation
in the N-MUF group at T2 in each of the performed tests,
whereas platelet aggregation remained unchanged in the
control group between T1 and T2. In the N-MUF group,
platelet aggregation increased approximately 18% in the
TRAPtest, 79% in the ASPItest, and 30% in the ADPtest,
whereas platelet aggregation in the control group did not
alter. Notably, arachidonic acid-induced platelet aggrega-
tion in the N-MUF group even reached the reference range
for normal platelet aggregation obtained by healthy volun-
teers (Figure 1). Analogue to our recent finding,16 the pres-
ent data indicated that arachidonic acid-induced platelet
aggregation might be the most sensitive test in MEA to re-
flect an improvement of CPB-induced platelet dysfunction.
Platelet aggregation at T2 was significantly higher in the
N-MUF group compared with the control group (Figure 1).diovascular Surgery c Volume 141, Number 5 1301
TABLE 2. Laboratory and thrombelastometric results at T1 and T2
T1 T2
Control group n ¼ 25 N-MUF group n ¼ 25 P Control group n ¼ 25 N-MUF group n ¼ 25 P
pH 7.4 (7.3/7.4) 7.4 (7.3/7.4) .185 7.4 (7.3/7.4) 7.4 (7.3/7.4) .977
Calcium [mmol/L] 1.28 (1.2/1.3) 1.2 (1.2/1.3) .157 1.2 (1.2/1.3) 1.2 (1.2/1.3) .512
Temperature [C] 36.3 (36/36.4) 36.3 (36/36.5) .837 36.4 (36.1/36.5) 36.3 (36.1/36.8) .747
Hematocrit [%] 26.1 (25.5/27.3) 25.5 (23.7/27.3) .341 27 (24.9/28.8) 26.7 (25.2/28.2) .402
Platelet count [/nL] 118 (90/146) 123 (95/143) .614 105 (70/141) 113 (91/132) .186
Fibrinogen [mg/dL] 169 (151/224) 193 (176/226) .095 163 (125/200) 176 (161/226) .201
INR 3.04 (2.6/3.9) 2.94 (2.5/3.64) .712 1.7 (1.58/1.94) 1.63 (1.55/1.9) .192
aPTT [s] >180 >180 1.0 50 (44/69) 59 (48/78) .261
CTEXTEM [sec] 113 (88/150) 100 (85/175) .251 92 (66/115) 95 (86/113) .568
MCFEXTEM [mm] 48 (41/54) 50 (45/54) .462 46 (36/52) 49 (43/55) .079
CTINTEM [sec] — — — 221 (195/272) 234 (173/274) .610
MCFINTEM [mm] — — — 44 (41/48) 46 (42/52) .176
MCFFIBTEM [mm] 8 (5.8/10) 7 (6/10) .486 8 (4.8/10) 7 (6/10) .676
CTHEPTEM [sec] 219 (197/247) 230 (183/271) .184 212 (191/263) 215 (173/241) .148
MCFHEPTEM [mm] 46 (39/54) 51 (48/55) .527 42 (35/47) 46 (40/52) .095
INR, International normalized ratio; aPTT, activated partial thromboplastin time; CT, clotting time; MCF, maximal clot firmness. Values are presented as the median (25th/75th
percentiles).
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MThis effect could be attributed to N-MUF, because patients
were randomized for this intervention and we detected no
significant group differences in the proportion of patients
preoperatively being treated with antiplatelet therapy, in
the amount of perioperatively transfused allogenic blood
products or coagulation factor concentrates (Table 1), or
in conventional laboratory coagulation analyses or basic
conditions for hemostasis (Table 2) at T1 and T2.
The beneficial effect of filtration on perioperative hemo-
stasis, even considering different variations in the tech-
niques used to perform filtration, has been shown in
numerous prospective noncontrolled studies18,19 and
a meta-analysis from 10 randomized trials, including
1004 patients undergoing cardiac surgery.20 Also, N-MUF
was associated with a significant reduction in perioperative
blood loss and transfusion requirements in both pediatric21
and adult patients undergoing cardiac surgery.18 Uncer-FIGURE 2. Postoperative blood loss. *P<.05; n ¼ 50.
1302 The Journal of Thoracic and Cardiovascular Surtainty remains concerning the exact mechanism that forms
the basis of the observed effects on perioperative hemosta-
sis. Journois and colleagues8 suggested that the observed
reduced postoperative blood loss after ultrafiltration may
be related to the removal of mediators of the inflammatory
response induced by CPB.
Secondary to mechanical fragmentation and destruction
of platelet functional integrity, platelet dysfunction was
attributed to the inflammatory response to CPB. In this con-
text, complement activation plays an important role in CPB-
induced platelet dysfunction.22 A correlation had been
shown among the degree of complement activation, platelet
dysfunction, and amount of postoperative blood loss.22,23
Remarkably, a reduction in complement activation was
associated with a decrease in blood loss,24 and the adminis-
tration of monoclonal antibodies against complement factor
C5a was even associated with a dose-dependent decrease in
postoperative blood loss.25 Platelet dysfunctions based on
CPB-induced generalized inflammation processes have
been studied as acquired qualitative and quantitative defi-
ciencies of adhesive platelet glycoprotein Ib and IIbIIIa re-
ceptors.26 These platelet surface receptors are essential
elements for platelet aggregation based on platelet–platelet
interactions, which are reflected by aggregation in the MEA
device.16 Filtration of the blood, independent of filter type,
filtration time point, or aspired volume balance, had been
shown to significantly reduce the inflammatory mediators,
including cytokines such as interleukin-6, interleukin-8,
and tumor necrosis factor-a, and complement factors such
as C3a and C5a.8,9,19,21 In view of these facts, the
observed simultaneous increase in platelet aggregation in
each of the 3 MEA tests after platelet stimulation with
thrombin-receptor-activating peptide, arachidonic acid, or
ADP led to the assumption that the filtration enhancesgery c May 2011
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Mglycoprotein Ib- or IIbIIIa-mediated platelet aggregation by
a reduction of inflammatory mediators.
Our data showed that the cumulative blood loss at 24
and 48 hours postoperatively was significantly lower in
the N-MUF group (Figure 2) compared with the control
group. These results might reflect a beneficial effect of
N-MUF on hemostasis but have to be interpreted with cau-
tion. The observed reduction in postoperative blood loss
seemed not be of clinical relevance because the amount
of transfused allogenic blood products or the proportion
of patients who required transfusion did not differ between
the groups.
Ultrafiltration was performed normovolemic and with no
concentrating effect. Thus, it was unsurprising to observe
that the performed conventional laboratory coagulation
analyses and thrombelastometry (aPTT, INR, CTHEPTEM,
CTINTEM; Table 2) reflected the heparin effect at T1 and
its reversal at T2 but did not show any significant influence
of N-MUF on hemostasis.
Study Limitations
There were some limitations in our study. First, we did
not perform any assays to study a potential change in the
number and function of platelet surface glycoproteins or
the concentration of inflammatory mediators. The results
of such tests would have been helpful to corroborate our hy-
pothesis that N-MUF improves ex vivo platelet aggregation
by enhancing glycoprotein-mediated platelet–platelet inter-
actions. However, it was the intention of our study to assess
the influence of N-MUF on parameters of point of care-
based and conventional coagulation analyses at the bedside.
Second, the study population was small, and the sample size
was based on the expected changes in platelet aggregation.
In particular, the observed reduction in postoperative blood
loss may be vulnerable to statistical errors. Third, ex vivo
platelet aggregation in MEA was considered to be depen-
dent of hematocrit. Transfusions of red blood cell concen-
trates were unavoidable within the study period in anemic
patients because of ethical considerations. However, we
detected no significant differences in the amount of perio-
peratively transfused packed red blood cells (Table 1) or
in the hematocrit at T1 and T2 in each study group or
between the groups (Table 2).
CONCLUSIONS
Despite these limitations, this study has important clini-
cal implications. In patients undergoing complex cardiac
surgery, N-MUF represents an approach to increase platelet
function.
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